drugset
Drugs / Clade C gp140
last change Nov 2023 re-read 2 minutes ago

Clade C gp140

also known as Clade C Glycoprotein (gp)140

Vaccine

Developed for
HIV infectious disease
Investigated by
Janssen Vaccines & Prevention B.V. · Beth Israel Deaconess Medical Center · Ragon Institute of MGH, MIT and Harvard · US Military HIV Research Program

Trials 5 · a red edge is where a trial was stopped

today NCT03307915 · Ph 1 NCT03060629 · Ph 2 NCT02935686 · Ph 1/2 NCT02788045 · Ph 1/2 NCT02685020 · Ph 1
20162017201820192020202120222023202420252026
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 12 trials
Phase 1 NCT03307915 Mar 2018 → Nov 2021 HIV infectious disease Janssen Vaccines & Prevention B.V. Completed No outcome recorded
Phase 1 NCT02685020 Mar 2016 → Jan 2018 — Janssen Vaccines & Prevention B.V. Completed No outcome recorded
Phase 1/22 trials
Phase 1/2 NCT02935686 Mar 2017 → Nov 2023 — Janssen Vaccines & Prevention B.V. Completed No outcome recorded
Phase 1/2 NCT02788045 Jul 2016 → Apr 2022 — Janssen Vaccines & Prevention B.V. Completed No outcome recorded
Phase 21 trial
Phase 2 NCT03060629 Nov 2017 → Feb 2022 — Janssen Vaccines & Prevention B.V. Terminated No outcome recorded

Evidence & citations 4 cited values

Every value below carries the sentence it was read from. 6 sources stand behind the page.

FieldValueCited text
Known as Clade C gp140 ClinicalTrials.gov intervention name — accepted as the source's own label NCT02935686 ↗
4

NCT03307915 ↗

NCT02685020 ↗

NCT02788045 ↗

NCT03060629 ↗
Known as Clade C Glycoprotein (gp)140 “Safety, Tolerability and Immunogenicity Study of Different Vaccine Schedules With Ad26.Mos.HIV and Clade C Glycoprotein (gp)140 in Healthy Human Immunodeficiency Virus...” NCT02685020 ↗
Modality Vaccine “The Clade C gp140 vaccine containing 250 mcg of total protein” NCT02685020 ↗
Route Intramuscular “All study interventions were administered intramuscularly.” PMID 32078815 ↗ Feb 2020